billHR7749•Event Monday, March 2, 2026Analyzed

To amend the National Quantum Initiative Act to make certain additions relating to quantum modeling and simulation, and for other purposes.

Neutral

Impact4/10

IBM ($IBM)Alphabet ($GOOGL)Microsoft ($MSFT)Honeywell ($HON)$DD $ECL Technology Manufacturing Healthcare

Summary

HR7749, the "Quantum in Practice Act," has been introduced in the House and referred to committee. This bill expands the National Quantum Initiative Act to include quantum modeling and simulation, signaling a future federal focus on practical quantum applications without authorizing direct funding. Companies with established quantum research divisions may benefit from this policy direction.

Key Takeaways

1.HR7749 expands the National Quantum Initiative Act to include quantum modeling and simulation, directing federal research priorities.
2.The bill does not authorize or appropriate direct funding; future financial allocations depend on separate appropriations bills.
3.Companies with established quantum research, particularly in molecular modeling and simulation, are structurally positioned to benefit from this policy direction.

Market Implications

The introduction of HR7749 signals a long-term federal commitment to advancing quantum modeling and simulation, which could benefit companies with significant R&D in this area. While there is no immediate financial impact due to the absence of direct funding, this policy direction could lead to increased federal grants and contracts in the future. Companies like $IBM, $GOOGL, and $MSFT, with their existing quantum computing initiatives, are aligned with this expanded federal focus. Sectors such as advanced materials ($DD, $HON) and specialty chemicals ($ECL) may see long-term benefits from the applications of quantum molecular simulations.

Full Analysis

HR7749, titled the "Quantum in Practice Act," was introduced in the House on March 2, 2026, and subsequently referred to the Committee on Science, Space, and Technology. This bill amends the National Quantum Initiative Act to specifically include quantum modeling and simulation within the definition of quantum information science and as a focus area for the Quantum Information Science Research Program. The bill is in an early legislative stage, having only been introduced and referred to committee. The bill does not authorize or appropriate any specific funding amounts. Instead, it directs federal research priorities by expanding the scope of the existing National Quantum Initiative Act. This means that while the policy direction is set, actual financial allocations for quantum modeling and simulation research would depend on future appropriations bills. The mechanism for potential benefits would be through federal research grants, contracts, and partnerships focused on these expanded areas, rather than direct procurement. Companies with significant existing investments in quantum computing and research, particularly those with capabilities in molecular modeling and simulation, are structurally positioned to benefit from this policy emphasis. This includes companies like $IBM, $GOOGL, and $MSFT, which have established quantum research divisions. Additionally, companies in sectors that stand to gain from advancements in quantum molecular simulations, such as materials science ($DD, $HON) and pharmaceuticals/chemicals ($ECL), could see long-term benefits from breakthroughs enabled by this research focus. The bill explicitly mentions applications in developing new fertilizers, medications, energy storage, and materials. Looking at recent market data, $IBM is currently at $246.74, up 4% over the last 7 days but down 3.82% over 30 days. $GOOGL is at $299.99, up 9.69% over 7 days but down 0.3% over 30 days. $MSFT is at $372.88, up 3.88% over 7 days but down 9.2% over 30 days. $HON is at $228.21, up 2.12% over 7 days but down 4.27% over 30 days. $DD is at $45.57, up 3.05% over 7 days but down 2.46% over 30 days. $ECL is at $267.03, up 1.73% over 7 days but down 6.94% over 30 days. These recent movements reflect broader market dynamics and are not directly attributable to the introduction of HR7749, given its early stage and lack of direct funding. The next legislative step for HR7749 would be consideration by the House Committee on Science, Space, and Technology.